Vanguard details 1.53M-share position in Keros Therapeutics (KROS)

Rhea-AI Filing Summary

The Vanguard Group reported beneficial ownership of 1,525,355 shares of Keros Therapeutics Inc common stock, representing 5% of the class as of 12/31/2025. Vanguard has shared voting power over 146,965 shares and shared dispositive power over all 1,525,355 shares, with no sole voting or dispositive power.

The shares are held for Vanguard’s clients, who have rights to dividends and sale proceeds, and no single client holds more than 5% of the class. Vanguard states the holdings are in the ordinary course of business and not for changing or influencing control of Keros. An internal realignment effective 01/12/2026 shifted portfolio management and proxy voting to certain subsidiaries, which are expected to report ownership on a disaggregated basis.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Keros Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

492327101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 492327101

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 146,965.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,525,355.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,525,355.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Keros Therapeutics Inc
(b)	Address of issuer's principal executive offices: 99 Hayden Avenue, Suite 120, Building E, Lexington, MA, 02421
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 492327101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1525355
(b)	Percent of class: 5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 146965
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1525355
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	01/30/2026

FAQ

What percentage of Keros Therapeutics (KROS) shares does The Vanguard Group report owning?

The Vanguard Group reports beneficial ownership of 5% of Keros Therapeutics common stock. This corresponds to 1,525,355 shares as of December 31, 2025, making Vanguard a significant institutional holder of the company’s equity.

How many Keros Therapeutics (KROS) shares does Vanguard have voting power over?

The Vanguard Group has shared voting power over 146,965 shares of Keros Therapeutics. It reports no sole voting power, indicating that voting decisions are shared, likely reflecting its role managing assets for multiple client accounts.

Does Vanguard control all 1,525,355 Keros Therapeutics (KROS) shares it holds?

Vanguard reports shared dispositive power over all 1,525,355 shares of Keros Therapeutics and no sole dispositive power. This means decisions to sell or otherwise dispose of these shares are made on a shared basis, generally for client accounts.

Are Vanguard’s Keros Therapeutics (KROS) holdings aimed at influencing control of the company?

Vanguard certifies the Keros Therapeutics shares were acquired and are held in the ordinary course of business. It states they were not acquired to change or influence control of the issuer, aside from activities tied to specific nomination rules.

Who ultimately benefits from Vanguard’s 5% stake in Keros Therapeutics (KROS)?

Vanguard states its clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds. It also notes that no single other person’s interest in the reported securities exceeds 5% of the class.

What internal changes at Vanguard affect its reporting of Keros Therapeutics (KROS) ownership?

Effective January 12, 2026, The Vanguard Group, Inc. no longer performs portfolio management or proxy voting. Certain subsidiaries or business divisions will report beneficial ownership separately, while continuing the same investment strategies used before the realignment.